One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

By Carl Zimmer on April 03, 2019
The Mysterious Hormone Called Klotho.

Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines

January 04, 2019
- Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing - Brings together a portfolio of potential medicines and technologies - Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman

Fortis Therapeutics Receives FDA Clearance of Two IND Applications for Novel Anti-CD46 Therapeutic for Treatment of Late-Stage Prostate Cancer and Multiple Myeloma

November 07, 2018
SAN DIEGO, November 6, 2018 – Fortis Therapeutics, Inc., an immuno-oncology biotech developing a novel antibody-drug conjugate (ADC) against CD46, today announced the U.S. Food and Drug Administration (FDA) has cleared two investigational new drug (IND) applications for the company’s lead candidate...

Principia Biopharma Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

September 25, 2018
Founded by Jack Taunton's laboratory at UCSF in 2012, Principia Biopharma began trading in September at a generous $17.00 per share for its initial public offering (IPO) on the Nasdaq, raising approximately $122.2 million.

Principia Biopharma, a UCSF Spinout, Seeks $86 Million IPO - Bay Area's 11th Life Sciences IPO This Year

August 22, 2018
A South San Francisco company — one of a handful trying to block an enzyme implicated in a number of diseases — filed to raise $86.2 million in an initial public offering.

ZeClinics and the University of California, San Francisco (UCSF) Join Forces Against Epilepsy

July 23, 2018
ZeClinics SL, a leading zebrafish preclinical CRO, announced today that it has signed a licensing agreement with the Office of Technology Management, now within UCSF Innovation Ventures, which leads licensing and business development efforts on behalf of the university for the commercialization of...

Research Breakthrough: Parker Institute for Cancer Immunotherapy (PICI) Scientists at UCSF and UCLA Have Published a Nature Paper on Non-viral Genome Editing in T-cells Using CRISPR

July 11, 2018
Using CRISPR, PICI scientists create faster, more precise way of engineering cancer-fighting T cells – without the use of expensive viruses